Gilead Sciences (GILD) has agreed to acquire private German biotech company Tubulis for $3.15 billion upfront in cash and up to $1.85 billion more should certain milestones be met, Bloomberg News reported Tuesday, citing people familiar with the matter.
An announcement could reportedly come as soon as Tuesday.
Gilead Sciences and Tubulis did not immediately reply to requests for comment from MT Newswires.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)